Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Jingxing Zhike Granules is a Traditional Chinese Medicine (TCM) product developed by Hunan Fangsheng Pharmaceutical. It was approved by China's National Medical Products Administration (NMPA) in 2021 for the treatment of pediatric acute tracheobronchitis, specifically for cases characterized by the "wind-cold transforming to heat" pattern. The formulation is designed to dispel wind, dissipate cold, clear heat, and resolve phlegm to alleviate coughing. Following its pediatric approval, the developer initiated Phase II clinical trials (such as CTR20230096) to evaluate the efficacy and safety of the granules in adult populations with acute tracheobronchitis presenting with similar TCM patterns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao'er jingxing zhike granules.